‹ ›
MYP_013612
← PREVIOUS NEXT → BACK
Basic Information
LP-69
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
not Standard
21 amino acids
-
contains X representing unresolved or non-standard residue
Sequence
IEELLKKAEEQQKKNEEELKX
Physicochemical Analysis
0.00 Da
0.00
0.00
0.00
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0000411 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
The 'X' at position 21 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antimicrobial Antiviral
T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells
0.00031 μM
IC50
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. J Virol. 2018 Sep 26;92(20):e01088-18. doi: 10.1128/JVI.01088-18. PMID: 30089693. PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0003972 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
The 'X' at position 21 is Lys-Chol(cholesterol)
Bio-Activity Profile
Antimicrobial Antiviral
HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells
0.002857-0.013512 μM
IC50
PaperPubMed PMID: 30867304 PMID30867304 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30867304/
RECORD: Rec_0006648 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 21 is Lys-Chol(cholesterol)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 NL4-3 (X4) | TZM-bl cells
0.00019992±0.00003269 μM
IC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperDesign and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. | Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y. | J Virol. 2019 May 15;93(11):e02312-18. | DOI:10.1128/JVI.02312-18 | PMID:30867304 PMID30867304 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30867304/
RECORD: Rec_0013681 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
The 'X' at position 21 is Lys-Chol(cholesterol)
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells
0.000149 μM
IC50
PaperPubMed PMID: 30867304 PMID30867304 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30867304/
RECORD: Rec_0014358 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 21 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
T-20 resistant HIV-1 NL4-3 (WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T) | TZM-bl cells
0.00201-1.81567 μM
IC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | Chong H, Zhu Y, Yu D, He Y. | J Virol. 2018 Sep 26;92(20):e01088-18. | DOI:10.1128/JVI.01088-18 | PMID:30089693 PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
1 2 3 ... 10 NEXT LAST
Showing 5 records on this page · Page 1 of 10